Potential bladder cancer therapeutic delivery systems: a recent update.

Abstract

Introduction: Bladder Cancer is one of the most expensive cancers to treat due to its high cost of therapy as well as the surveillance expenses incurred to prevent disease recurrence and progression. Thus, there is a strong need to develop safe, efficacious drug formulations with controlled drug release profiles and tumor-targeting potential, for improved therapeutic outcomes of bladder cancer patients.

Areas covered: This review aims to provide an overview of drug formulations that have been studied for potential bladder cancer treatment in the last decade; highlight recent trends in bladder cancer treatment; mention ongoing clinical trials on bladder cancer chemotherapy; detail recently FDA-approved drug products for bladder cancer treatment and identify constraints that have prevented the translation of promising drug formulations from the research laboratory to the clinics.

Expert opinion: This work revealed that surface functionalization of particulate drug delivery systems and incorporating the nanoparticles into in situ gelling systems could facilitate controlled drug release for extended periods, and improve the prognosis of bladder cancer treatment. Future research directions could incorporate multiple drugs into the drug delivery systems to treat advanced stages of the disease. In addition, smart nanomaterials, including photothermal therapies, could be exploited to improve the therapeutic outcomes of bladder cancer patients.